References
- Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, . Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723–6.
- Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K, . Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents 2009; 33:98–9.
- Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, . Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 2011;55:1867–73.
- Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 1988;32:1320–2.
- Lovering AM, Zhang J, Bannister GC, Lankester BJ, Brown JH, Narendra G, . Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50:73–7.
- Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet 2000;39:167–83.
- Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, . Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18–55.
- Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O’Grady M, . Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003;47:2775–80.
- Lin YH, Wu VC, Tsai IJ, Ho YL, Hwang JJ, Tsau YK, . High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 2006;28:345–51.
- Soriano A, Ortega M, Garcia S, Penarroja G, Bove A, Marcos M, . Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007;51:2559–63.
- Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, . High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 2006;42:66–72.
- Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, . Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010;36:179–81.
- Hiraki Y, Tsuji Y, Hiraike M, Misumi N, Matsumoto K, Morita K, . Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 2012;44:60–4.
- Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, . Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2011;17:70–5.